Press Releases

July 27, 2017

The funding will be used to support discovery and preclinical development of a new class of antibiotic that circumvents beta-lactam antibiotic resistance, but with the same safe and effective mechanism of action of beta-lactams.

July 25, 2017

Proceeds will be used to advance the Venatorx Pharmaceuticals' portfolio, including lead product candidate VNRX-5133 for multi-drug resistant (MDR) gram-negative infections.

Archive: 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010